Fatty Acid Amide Hydrolase in Prostate Cancer: Association with Disease Severity and Outcome, CB1 Receptor Expression and Regulation by IL-4 by Thors, Lina et al.
Fatty Acid Amide Hydrolase in Prostate Cancer:
Association with Disease Severity and Outcome, CB1
Receptor Expression and Regulation by IL-4
Lina Thors
1, Anders Bergh
2, Emma Persson
3, Peter Hammarsten
2,P a ¨r Stattin
4, Lars Egevad
5, Torvald
Granfors
6, Christopher J. Fowler
1*
1Pharmacology Unit, Department of Pharmacology and Clinical Neuroscience, Umea ˚ University, Umea ˚, Sweden, 2Pathology Unit, Department of Medical Biosciences,
Umea ˚ University, Umea ˚, Sweden, 3Departments of Oncology and Radiation Sciences, Umea ˚ University, Umea ˚, Sweden, 4Urology and Andrology Unit, Department of
Surgical and Perioperative Sciences, Umea ˚ University, Umea ˚, Sweden, 5Department of Pathology and Cytology, Karolinska University Hospital, Stockholm, Sweden,
6Department of Urology, Central Hospital, Va ¨stera ˚s, Sweden
Abstract
Background: Recent data have indicated that there may be a dysregulation of endocannabinoid metabolism in cancer. Here
we have investigated the expression of the endocannabinoid metabolising enzyme fatty acid amide hydrolase (FAAH) in a
well characterised tissue microarray from patients diagnosed with prostate cancer at transurethral resection for voiding
problems.
Methodology/Principal Findings: FAAH immunoreactivity (FAAH-IR) was assessed in formalin-fixed paraffin-embedded
non-malignant and tumour cores from 412 patients with prostate cancer. CB1 receptor immunoreactivity (CB1IR) scores
were available for this dataset. FAAH-IR was seen in epithelial cells and blood vessel walls but not in the stroma. Tumour
epithelial FAAH-IR was positively correlated with the disease severity at diagnosis (Gleason score, tumour stage, % of the
specimen that contained tumour) for cases with mid-range CB1IR scores, but not for those with high CB1IR scores. For the
281 cases who only received palliative therapy at the end stages of the disease, a high tumour epithelial FAAH-IR was
associated with a poor disease-specific survival. Multivariate Cox proportional-hazards regression analyses indicated that
FAAH-IR gave additional prognostic information to that provided by CB1IR when a midrange, but not a high CB1IR cutoff
value was used. Interleukin-4 (IL-4) receptor IR was found on tumour epithelial cells and incubation of prostate cancer PC-3
and R3327 AT1 cells with IL-4 increased their FAAH activity.
Conclusions/Significance: Tumour epithelial FAAH-IR is associated with prostate cancer severity and outcome at mid-range,
but not high, CB1IR scores. The correlation with CB1IR in the tumour tissue may be related to a common local dysregulation
by a component of the tumour microenvironment.
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Introduction
Prostate cancer is the commonest cancer form in males.
According to the U.S. National Cancer Institute (http://www.
cancer.gov/cancertopics/types/prostate), the number of new cases
of prostate cancer in the United States in 2009 was 192,280, and
the number of deaths due to the disease was 27,360. Treatment
options range from expectancy to prostatectomy, hormonal
treatment and radiation depending upon the nature of the cancer.
In recent years, evidence has accumulated to suggest that the
endocannabinoid system, comprising the cannabinoid CB1 and
CB2 receptors, their endogenous ligands anandamide and 2-
arachidonoylglycerol, and their synthetic and degradative en-
zymes, plays a role in the pathogenesis and possible treatment of
cancer types, including prostate cancer (for recent reviews, see
[1–3]). Thus, for example, cannabinoids produce a CB receptor-
mediated apoptosis in glioma cells as a result of a sustained
production of ceramide [4] and several papers have reported both
CB receptor-dependent and -independent effects of cannabinoids
upon the viability, mobility and invasivity of both androgen-
sensitive and insensitive prostate cancer cell lines [5–11].
In vitro, a local endocannabinoid tone is an important factor
controlling the malignancy of prostate cancer cells. Thus,
modulation of the levels of endocannabinoids, by use of inhibitors
of endocannabinoid synthesis or metabolism, results in a change in
the invasive properties of prostate cancer cells in a manner
consistent with a protective effect of endocannabinoids [8,12]. The
endocannabinoid anandamide is metabolised by the enzyme fatty
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PC-3 cells results in a phenotype with an increased invasive
behaviour in vitro [12]. Those authors concluded that ‘‘inhibition of
FAAH activity by specific inhibitors may be one therapeutic target
for the treatment of prostate cancer’’ [12]. FAAH inhibitors,
which do not produce the sort of central behavioural effects
associated with cannabinoids like D
9-tetrahydrocannabinol [13],
are currently in drug development, primarily with pain as a
therapeutic target, and the leading compound is in phase II of its
development.
Less is known about the endocannabinoid system in prostate
tumour tissue, but in a study using a large number of patients with
a long follow-up, we recently reported that the expression of CB1
receptors in tumour tissue obtained at diagnosis was associated
with disease severity and outcome [14]. Thus, individuals with a
CB1 receptor immunoreactivity (CB1IR) above or equal to the
median score for the data set had a higher incidence of metastases
at diagnosis, and a higher proportion of cases with a high Gleason
score (an indicator of disease severity based on the morphology of
the two most common tumour types in the sample [15]) than those
individuals with a CB1IR below the median for the data set.
Furthermore, for the individuals who had been followed by
expectancy until appearance of metastases, a high CB1IR score
was associated with a lower disease-specific survival [14]. With
respect to FAAH, it has been reported that in a commercially
available tissue microarray, cores from prostate cancer tissues had
a higher expression of the enzyme than seen in normal tissue [12].
However, no data on the relation between the FAAH immuno-
reactivity (FAAH-IR) and disease outcome was presented. In
addition, possible reasons for the high level of FAAH-IR in the
tumour tissue were not investigated by these authors. In con-
sequence, in the present study, we have investigated the FAAH-IR
in the tissue microarray used previously by us to characterise
CB1IR in the tumour tissue [14], and undertaken studies using
cultured cells to see if a known component of the tumour
microenvironment can affect the FAAH activity. Further, we have
investigated whether FAAH-IR is correlated with other pathoge-
netic and prognostic variables, such as the local tumour stage
number and the immunoreactive score for phosphorylated
epidermal growth factor receptor (pEGFR).
Methods
Ethics Statement
The research ethical committee at Umea ˚ university hospital
(Regional Ethical Review Board in Umea ˚, Sweden) approved of
the study and waived the need for informed consent.
Patients
The formalin-fixed, paraffin-embedded samples used in the
present study were collected at the Central Hospital, Va ¨stera ˚s,
Sweden, between 1975 and 1991 from a total of 412 patients
diagnosed with prostate cancer at transurethral resection for
micturation difficulties [16]. The presence of metastases was
determined using a bone scan shortly after the transurethral
resection. The patients were followed until 2003. For the 388 cases
where tumour FAAH-IR could be scored (see below), 281 were
followed by watchful waiting until the appearance of metastases (the
standard treatment approach at the time). The other patients
received hormonal treatment, radiotherapy or radical prostatecto-
my. The Gleason scores and the percentage of the specimen that
contained tumour were assessed in each sample. Cause of death was
assessed by evaluation of medical records. Tissue microarrays (cores
with a diameter of 0.6 mm) were constructed using a Beecher
Instrument (Sun Prairie, WI, USA). Each tissue microarray slide (56
in total, usually with cores from 8 cases per slide) contained up to
eight (usually five) samples of tumour tissue (both primary and
secondary Gleason grade areas were included) and up to four
(usuallyfour)samplesofnon-malignanttissuefromeachpatient[16].
Immunohistochemistry
Sections were deparaffinized, rehydrated and placed in citrate
buffer pH 6.0. After boiling in a pressure cooker for 60 min,
samples were placed in water and then in Ventana buffer, after
which they were placed in a Ventana automated analyser (Ventana
Medical Systems Inc., Tucson, AZ) to which the FAAH antibody
(dilution 1/2000) and the secondary system (iVIEW DAB Detection
Kit, Ventana Medical Systems Inc.) were added. The antibody
used, a rabbit anti-FAAH raised against the last 102 amino acids of
rat FAAH, has been characterised in detail [17] and was found to
produce the appropriate staining pattern (somatodendritic staining
of principal cells) in formalin-fixed tissue from human hippocampus
(data not shown), consistent with the rat hippocampus [18,19]. CB1
receptor immunoreactivity (CB1IR) scores were available in the
database, and have been reported elsewhere [14].
The individual cores were scored under the microscope for
FAAH-IR by an investigator (LT) who was blind to the clinical
data for the patients. The scoring system used was essentially the
same as that used previously for CB1IR [14]. In brief, for the
epithelial tissue, the cores were scored for immunoreactive
intensity (0–3 where 0 is absent and 3 is high) and distribution
within the epithelial tissue (0, 10, 25, 33, 50, 67 or 100% of the
total distribution for each intensity). The distribution for the most
common intensity was set to 100 minus the sum of the other
intensities. The fractional distribution at each intensity was
multiplied with the intensity score and the values summed to give
a final score for the core. Thus, for example, a core with intensities
of 1 (10%), 2 (10%) and 3 (remainder) (distribution in brackets)
would receive a composite score of 160.1+260.1+360.8=2.7.
When identifiable in the core, the basal and luminal epithelial
tissue was scored separately. Blood vessel walls were scored in the
same way, but with a simpler distribution (0, 50 and 100%).
Throughout the scoring, examples of cores scored as 1, 2 and 3
were on hand for comparison as an ‘‘internal standard’’. Cores
where the structure or quality of the tissue was not sufficiently
good or where the staining was unclear were excluded from the
study. For each measure, the median values for the composite
scores for each patient were calculated and entered into the
database by a second investigator (CF). As a measure of the
reliability of the tumour epithelial scores, 67 cores (16 patients)
were scored at two separate occasions by the same investigator.
The Spearman correlation coefficient for the individual core scores
between this pilot and the main study was 0.76 (n=67, p,0.0001,
95% confidence interval 0.63–0.85). The intraclass correlation
coefficient for single measures (ICC(2,1), a measure of the
reproducibility of the scoring method) was 0.67 (95% confidence
interval 0.51–0.78, p,0.001).
Interleukin-4 (IL-4) receptor immunoreactivity was assessed in
formalin fixed, paraffin embedded tissue slices using a monoclonal
antibody to the extracellular domain of the recombinant human
IL-4 receptor (MAB230, R&D Systems Inc., Minneapolis, USA).
The antibody dilution was 1/200 and the immunoreaction was
detected using the Ventana detection system as above. Lymph
node tissue served as a positive control.
Culturing of cells
PC-3 and LNCaP human prostate cancer cells (passage ranges
32–38 and 14–19, respectively), and R3327 AT-1 rat prostate
FAAH in Prostate Cancer
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ment. PC-3 cells were cultured in Hams F-10, 2mM L-glutamine,
10% foetal bovine serum and 100 ml
21 penicillin +100 g ml
21
streptomycin (PEST). LNCaP cells were cultured in RPMI 1640,
2 mM Glutamine, 10% foetal bovine serum and PEST. R3327
AT-1 cells were cultured in RPMI 1640, 250 nM dexamethasone,
10% foetal bovine serum and PEST. P19 mouse embryonic
carcinoma cells (passage range 17–19) were obtained from the
European Collection of Cell Cultures (Porton Down, UK). P19
cells were cultured in MEM alpha 22571 with 10% foetal bovine
serum, 1% nonessential amino acids and and PEST. Cells were
grown in 75 cm
2 culturing flasks at 37uC with 5% CO2 in
humidified atmospheric pressure. Cells were passaged twice a
week and cell culture medium was changed three times a week.
Interleukin-4 (IL-4) stimulation of FAAH activity in
cultured cancer cells
The cells were plated at a density of 1610
6 cells per well in 6-
well plates. Following incubation overnight at 37uCi na n
atmosphere of 5% CO2, the cell culture medium was changed,
to medium supplemented with IL-4, and incubated for an
additional 24 hours. Cells were washed twice with ice-cold
phosphate-buffered saline (PBS) and thereafter collected using a
rubber policeman. On ice, cells were resuspended in PBS,
centrifuged for 5 minutes at 10006g and pellet resuspended in
10 mM Tris buffer at pH 9. The homogenates were stored at
280uC in aliquots until used. The protein content was determined
using bovine serum albumin as standard [20].
The FAAH activity was measured as described by Boldrup et al.
[21]. Briefly, following incubation of homogenates with 2 mMo f
[
3H]AEA labelled in the ethanolamine part of the molecule (assay
pH 9), a charcoal mixture (80 ml charcoal +300 ml 0.5 M HCl per
tube) were added and tubes were placed on ice to stop the
reaction. The charcoal was then sedimented by centrifugation,
25006g for 10 minutes, and aliquots of the supernatant were
transferred to scintillation vials and tritium content was deter-
mined by liquid scintillation spectroscopy with quench correction.
Blank values are defined as the accumulated amount of tritium for
assays performed in the absence of homogenates.
RNA extraction and cDNA synthesis
PC-3 and LNCaP cells were plated at a density of 1610
6 cells
per well in 6-well plates and treated with IL-4 as described above.
For PCR analysis, total RNA was extracted using the miRNeasy
Kit (Qiagen, Hilden, Germany) according to the instructions by
the manufacturer. The RNA concentration was measured using a
Nanodrop instrument (Thermo Scientific, Wilmington, DE, USA),
and cDNA was synthesized from 2 mg of total RNA using a cDNA
synthesis kit with random primers (High capacity cDNA reverse
transcription kit; Applied Biosystems, Foster City, CA, USA). For
semi-quantitative PCR, samples from the same treatment group
were pooled (n=6).
Semi-quantitative PCR
The mRNA levels for human CB1, FAAH and GAPDH were
analysed using a Taq PCR Core kit (Qiagen, Hilden, Germany), a
Biometra TProfessional thermocycler (Biometra, Go ¨ttingen,
Germany) and the following primers: hFAAH (197 bp), for-
ward 59-TGGAAGTCCTCCAAAAGCCCAG-39, reverse 59-
TGTCCATAGACACAGCCCTTCAG-39, hCB1 (165 bp), for-
ward 59- AAGGTGACATGGCATCCAAAT-39, reverse 59-AG-
GACGAGAGAGACTTGTTGTAA-39, and hGAPDH (180 bp),
forward 59- CAACTACATGGTTTACATGTTC-39, reverse
59- GCCAGTGGACTCCACGAC-39. The conditions for PCR
were: denaturing at 94uC for 2 min, annealing for 40 s at 57uC
(GAPDH) or 60uC (FAAH, CB1) followed by elongation at 72uC
for 60 s; in subsequent cycles denaturing was performed at 94uC
for 40 s. For FAAH and CB1, the analyses included 35 cycles,
whereas 25 cycles were used for GAPDH.
Quantitative real-time PCR
In addition to semi-quantitative PCR on pooled samples,
analysis of individual samples was performed using quantitative
real-time PCR. Both SYBR Green (FAAH, CB1, GAPDH) and
TaqMan (ß-actin) kinetics were used. For FAAH, CB1 and
GAPDH, the primers described above were used together with
Power SYBR Green PCR Master Mix (Applied Biosystems, Foster
City, CA, USA), whereas human ß-actin was detected using a pre-
made primer-probe mix (Hs00357333_g1, Applied Biosystems)
together with TaqMan Universal PCR Master Mix (Applied
Biosystems). The amplifications were performed on an ABI
PRISM 7900 HT Sequence Detection System and software
(Applied Biosystems), and the samples were analysed in triplicates.
Both GAPDH and ß-actin were used as housekeeping genes, with
similar results (data for ß-actin not shown). The relative expression
of FAAH and CB1was calculated from Ct values using the standard
curve method.
Western Blot
For Western blotting, protein samples were electrophoresed on
10% SDS – polyacrylamide gels under reducing conditions and
fractionated proteins were electrophoretically transferred onto
Immobilon-P membrane (Millipore, Bedford, MA, USA). Mem-
branes were blocked over night at 4uC on an orbital shaker in 5%
non-fat powdered milk, 0.05% Tween-20 in PBS (PBS- T) prior to
incubation with primary rabbit polyclonal antibody against FAAH
(1:1000–1:5000; the same antibody as used in the immunohisto-
chemical part of the study) or primary rabbit polyclonal antibody
against actin (1:8000; Sigma-Aldrich, St Louis, MO, USA).
Primary antibodies were diluted in PBS-T 3% (FAAH) or PBS-
T 5% (actin) non-fat powdered milk. After incubation with
peroxidase-conjugated secondary antibodies (Amersham Biosci-
ences), proteins were detected using enhanced chemiluminescence
detection system (Amersham Biosciences). Molecular sizes of
protein bands were determined by parallel electrophoresis of
molecular weight markers (Bio-Rad Laboratories AB, Sundby-
berg, Sweden). Protein concentrations were determined by BSA
protein assay kit (Pierce, Rockford, IL, USA).
Compounds
Anandamide (ethanolamine-1-
3H; specific activity: 2.2 TBq
mmol
21) was obtained from American Radiolabeled Chemicals
Inc. (St Louis, MO, USA). Unlabelled anandamide and URB597
were obtained from the Cayman Chemical Co. (Ann Arbor, MI,
USA). Interleukin-4 was obtained from Sigma-Aldrich.
Statistics
With the exception of the Cox proportional-hazards regression
and intraclass correlation coefficient analyses, which were
conducted using SPSS software (SPSS Inc., Chicago, IL, USA),
all statistical calculations were undertaken using the statistical
package built into the GraphPad Prism 5 computer programme
for the Macintosh (GraphPad Software Inc., San Diego, CA,
USA). For survival analyses, an event was defined as death due to
prostate cancer and entered into the database as ‘‘event=1’’.
Death from other causes was censored, as were the cases where the
FAAH in Prostate Cancer
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grouped as ‘‘event=0’’. Cases (n=3) where the disease outcome
was unknown were excluded from the survival analyses. The
duration of event-free survival is defined as the time from diagnosis
until the date of prostate cancer death, death of other causes, or if
no death occurred, until the date of last follow-up.
Receiver operating characteristic (ROC) curves were used to
define cut-offs for FAAH-IR, which were then used to construct
survival curves using the Kaplan-Meier method. Differences in
outcome between groups were tested with the log-rank test. Cox
proportional-hazards regression analyses were undertaken to
assess the influence of the FAAH score upon the outcome at
different CB1IR cutoffs. Differences in the distribution of variables
between groups of patients were analyzed using the chi-square test.
For readers unfamiliar with the statistical methods used to assess
the influence of FAAH-IR upon disease outcome, a brief
explanation of their usefulness is warranted, particularly with
respect to the choice of cutoff values for FAAH-IR. The ROC test
was originally developed to aid interpretation of radar signals, and
plots the number of true negatives (1- the false positive fraction,
termed 1 - specificity) vs. true positives (sensitivity) at a given cutoff
value (i.e. for cases with a score equal to, or higher than, the
selected value). The area under the ROC curve can then be
calculated. For a test with absolutely no diagnostic value, the curve
will be a straight line with an area of 0.5. A perfect test would give
a value of 1.0, so the further away from 0.5 the value, the better
the test. For a test with an area under the curve significantly
greater than 0.5, an important issue is the choice of cutoff, the
value chosen as a signal that the patient may have the disease in
question. If the cutoff value is set low, then the sensitivity will be
high, but there will be a large number of false positives. If the
cutoff value is set high, then the number of false positives will be
lower, but a large number of true positives will be missed. The
choice of cutoff is thus a trade-off between maximising the number
of true positives found and minimising the number of false
positives. Choice of cutoff is dependent upon the relative
importance of missing true positives vs. misdiagnosing true
negatives for the disease in question, but a useful way of
identifying an optimal cutoff is to determine the cutoff point with
the maximal vertical distance between the observed value and the
corresponding value for a test with no diagnostic value, calculated
as maximum sensitivity + specificity -1. This value is termed the
Youden index, J, and we have used this value here for FAAH-IR
(termed JFAAH). For useful reviews on ROC curves and the choice
of optimal cutoff values, see [22–24].
With respect to the statistical analyses of survival curves, the
Kaplan-Meier method, where differences in outcome between
groups is tested with the log-rank test, provides a useful (and visual)
method for assessing differences in survival curves. The Cox
proportional-hazards regression analyses the hazard ‘‘as a function
of the explanatory variables and unknown regression coefficients
multiplied by an arbitrary and unknown function of time’’ (citation
from the original paper of Cox [25]), i.e. assesses the contribution
of different potential risk factors on the end-point measured (in this
case, death due to prostate cancer) without making assumptions
about the basic survival curve itself.
Results
Distribution of FAAH immunoreactivity in non-malignant
and tumour tissue
FAAH-IR was scored in cores from a total of 412 patients. Of
these, records for six patients were not found in the data base, and
so data for these patients were not included in the analyses.
An example of the FAAH-IR for the non-malignant tissue is
shown in Fig. 1A. FAAH-IR was seen in the epithelial cells, and in
blood vessels, as well as in cells (possibly lymphocytes, which
express FAAH [26]) infiltrating the stroma in some cores. In all,
1247 cores from 377 patients were scored for non-malignant
epithelial FAAH. Of these, 733 cores from 307 cases had definable
basal : luminal morphology and the FAAH-IR for these cases were
scored separately and used in the analyses. In addition, 993 cores
from 369 cases were scored for FAAH-IR in the blood vessel walls.
The cumulative distribution of the scores in the basal and luminal
epithelial cells is shown in Fig. 1B, where it is clear that the median
FAAH-IR is higher in the basal epithelial cells than in the luminal
cells. In fact, of the 733 cores scored, the basal FAAH-IR score
was higher than the corresponding luminal score in 724 cores and
the two scores were equal in 9 cores. The luminal score was never
higher than the basal score. The blood vessel FAAH-IR was
scored slightly differently, so a direct comparison of the values is
not relevant. However, there was a significant correlation between
basal FAAH-IR and blood vessel FAAH-IR, but not between the
luminal and blood vessel FAAH-IR (Table 1).
A total of 1851 cores from 388 cases were scored for FAAH-IR
in the tumour epithelial cells. For the blood vessels, 1201 cores
from 360 patients were scored. An example of the staining for a
tumour core is shown in Fig. 1C and the cumulative distribution of
the epithelial scores are shown in Fig. 1B, where it can be seen that
the median score was significantly higher than the non-malignant
luminal score, but lower than the basal score.
The samples used here have previously been investigated by us
with respect the expression of epithelial CB1 receptors [14]. For
the non-malignant samples, there was no significant correlation
between the CB1IR scores and either basal, luminal or blood vessel
FAAH-IR. In contrast, a significant correlation between the
tumour CB1IR and the tumour epithelial and blood vessel FAAH-
IR was seen (Table 1).
FAAH activity in prostate cancer cell lines is affected by
interleukin-4
One explanation for the finding that the tumour epithelial FAAH-
IR is higher than FAAH-IR in normal prostate epithelial tissue [12]
is that a constituent of the tumour microenvironment affects its
activity. The TH2 cytokine interleukin-4 (IL-4), which has been
reported to regulate FAAH and CB1 receptors in lymphocytes and
Jurkat cells [26–28], is involved the pathogenesis of several cancer
types, including prostate cancer (see [29–35]). IL-4 receptors have
been reportedinbothtumour epithelial cellsand inculturedprostate
cancer cell lines [29,36]. We confirmed the presence of IL-4 IR in
prostate cancer epithelial tissue (Fig. 2A), and found that incubation
of both human androgen-insensitive PC-3 cells and rat Dunning
R3327 AT-1 prostate cancer cells with IL-4 for 24 h produced a
significant increase in FAAH activity of the cells (Fig. 2B and C). A
similar result was seen with human prostate cancer LNCaP cells
(data not shown). This effect of IL-4 is not unique to prostate cancer
cells,sinceitwasalsoseenmouseP19teratocarcinomacells(Fig.2D).
In subsequent experiments, the effects of IL-4 treatment upon
FAAH protein and mRNA were assessed. Treatment of PC-3 and
LNCaP cells with IL-4 for 24 h did not regulate the mRNA
expression of FAAH, as assessed by both semi-quantitative PCR
and quantitative real-time PCR (Fig 2E, 2F). In an additional
experiment, PC-3 cells were treated with IL-4 (5 ng/ml) for 3 h, to
study possible early regulation of FAAH expression. Similar to the
24 h experiment, however, treatment of PC-3 cells with IL-4 for
3 h did not regulate the mRNA expression of FAAH (data
not shown). In contrast to the situation for Jurkat cells and
T-lymphocytes, the expression of CB1 in LNCaP cells was not
FAAH in Prostate Cancer
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untreated controls, means 6 s.e.m., n=6) following 24 h of
treatment with either vehicle or IL-4 was 100633 and 109620,
respectively. The PC-3 cells used in our lab did not express
detectable levels of CB1 mRNA (data not shown).
Preliminary Western blots analyses were also undertaken using
lysates from PC3 cells treated for 24 h with either vehicle or
5 ng/ml IL-4. In addition to the expected molecular weight band,
additional bands were seen suggesting that there may be protein
aggregation and some breakdown in the lysates, post-translational
protein modification by the cells, and/or that the assay protocol
was not fully optimised, although three different dilutions of the
primary antibody were used. However, none of the bands showed
any obvious difference in intensity following IL-4 treatment,
protein loading being confirmed with actin blots (data not shown).
FAAH-IR in the tumour tissue: correlation with disease
severity at diagnosis
In Table 2, the correlation coefficients for the tumour FAAH-IR
and clinical variables determined at diagnosis are listed. For the
complete dataset, there was a significant positive correlation of the
epithelial, but not blood vessel, FAAH-IR with both the Gleason
score and the % of specimen that contained tumour, whereas
neither score correlated significantly with the incidence of
metastases at diagnosis. A correlation was also seen for the
epithelial, but not blood vessel FAAH-IR with the local stage
number, the immunoreactive score for phosphorylated epidermal
growth factor receptor (pEGFR, a marker for prostate cancer
outcome [37], Table 1), and with cytoplasmic, but not nuclear
HER2 (human EGF receptor 2, data not shown). No significant
correlation was seen between either epithelial or blood vessel
Figure 1. FAAH immunoreactivity in formalin-foxed prostate cancer samples. Panel A. Example of FAAH-IR in a core of non-malignant
prostate tissue obtained at transurethral resection from a 75 year old patient. The asterisks indicate blood vessels, and the # symbol indicates FAAH
positive cells, presumably infiltrating lymphocytes. In Panel C, the FAAH-IR in a core of tumour tissue from a 64 year old patient is shown. The lines at
the top right above the cores indicate 100 mm. Panel B shows the cumulative frequencies of FAAH-IR scores for the basal and luminal non-malignant
(N) epithelial tissue (n=307 in both cases) and for the tumour (T) epithelial tissue (n=388). The median values (with interquartile range in brackets)
were: basal (N), 2.625 (2.125–2.9); luminal (N), 1.25 (1–1.75); epithelial (T), 2.05 (1.8–2.3). The median values were significantly different from each other
(p,0.001, Dunn’s multiple comparison test following significant Kruskal-Wallis test). Panel D shows the relation of the epithelial tumour FAAH-IR to
the Gleason score (GS) at diagnosis. The FAAH-IR scores were divided into quadrants where I refers to scores between ,1.8 (n=96), II between 1.8
and 2 (n=94), III between 2.05 and 2.25 (n=99) and IV between 2.3 and 3 (n=99). The distribution of the GS groups was significantly different in the
quadrants (x
2=27.03, df=9, p,0.0005).
doi:10.1371/journal.pone.0012275.g001
FAAH in Prostate Cancer
PLoS ONE | www.plosone.org 5 August 2010 | Volume 5 | Issue 8 | e12275FAAH-IR and either the immunoreactive score for non-phos-
phorylated EGFR or the tumour vascular density (number of vWf-
stained vessels; number of endoglin stained vessels) (data not
shown). In the tumour stroma, the androgen receptor expression is
inversely related to disease severity and outcome [38]. However,
there was no significant correlation between the epithelial or blood
vessel tumour FAAH-IR and the stroma androgen receptor IR in
the 69 (epithelial) or 57 (blood vessel) cases which had been scored
for both parameters (data not shown).
The correlation between the Gleason scores and the tumour
epithelial FAAH-IR is illustrated in Fig. 1D, where the FAAH-IR is
divided into four approximately equal (in sample size) ranges, from
the lowest (‘‘I’’) to the highest (‘‘IV’’). As the FAAH-IR increases
from I to IV, the number of cases with Gleason scores 4–5
decreases, and the number of cases with Gleason scores 8–10
increases. Thus, the FAAH-IR correlates with disease severity at
diagnosis, despite the fact that the median FAAH-IR scores for each
Gleason group are not that different (2 (n=88), 2.075 (n=102),
2.075 (n=66) and 2.1 (n=132) for Gleason scores of 4–5, 6, 7 and
8–10, respectively). Further analysis indicated that the significant
correlation of the tumour epithelial FAAH-IR with the Gleason
score wasseen for mid-range CB1IR scores,butnot for either lowor
high CB1IR scores (Table 2). The correlation with the tumour stage
and the % of specimen that contained tumour was also dependent
upon the CB1IR range used, being negative at low CB1IR scores,
positive at the median CB1IR score (2), and not being seen at the
highCB1IR scores.Thecorrelation withpEGFRwasnotsignificant
when the data was subdivided into the CB1IR quadrants (Table 1),
suggesting that the correlation with FAAH-IR reflects a primary
correlation of this measure with the CB1IR. Indeed, the correlation
between tumour epithelial pEGFR and CB1IR was highly
significant (Spearman’s r value 0.30, n=280, p,0.001).
Tumour epithelial FAAH-IR is associated with disease
outcome
During the period when the specimens were collected, the
standard treatment for prostate cancer was watchful waiting until
the appearance of metastases. Thus, a substantial proportion of the
samples represent essentially untreated patients, which allows for
the evaluation of the association of biological parameters measured
at diagnosis upon the outcome of the disease. Receiver operating
characteristic (ROC) analyses were undertaken on the data subset
for the untreated patients (for an explanation of the methodology to
the reader not well versed in this statistical approach, see the
statistics section of Methods). For the tumour epithelial FAAH-IR,
the area under the ROC curve using a 15 year cutoff (259 cases)
was significantly above 0.5, and the optimal cutoff point (Youden
Index, here termed JFAAH) for the epithelial FAAH-IR was
determined to be at a score of .2.354 (Fig. 3A). The area under
the ROC curve for the blood vessel FAAH-IR was not significantly
different from 0.5 (Fig. 3A). Using this JFAAH, Kaplan-Meier
analyses demonstrated a significant contribution of tumour
epithelial FAAH-IR upon the disease outcome (Fig. 3B). The
median survival (i.e. the time at which fractional survival is 50%)
was 18.1 vs. 10 years for the patients with an FAAH-IR below vs.
above JFAAH. The hazard ratio for the two curves(Mantel-Haenszel
method) was 2.574 (95% confidence interval 1.418–4.671).
COX proportional-hazards regression analyses were undertaken
using different cutoff values for CB1IR to assess the extent to which
FAAH-IR provided additional prognostic information to that given
by the CB1IR score. Using a cutoff CB1IR value of $2 (the cutoff
used in [14]), a significant contribution by FAAH-IR was seen in
the multivariate analysis (Table 3). A similar significance was seen
using a CB1IR cutoff value of $2.1 (FAAH Exp(B)=1.969,
p,0.01). However, at a CB1IR cutoff of $2.3, the significant
contribution of FAAH was lower (Table 1), and at a CB1IR cutoff
of $2.5, the contribution of FAAH was lost (FAAH Exp(B)=1.623,
p=0.073). The contribution by CB1IR was significant at all cut-
offs. These data indicate that the additional information provided
by FAAH-IR decreases as the CB1IR cut-off used increases. In
contrast to CB1IR [14], Cox proportional-hazards regression
analyses indicated that FAAH-IR did not provide additive
prognostic information to Gleason scores (data not shown).
Discussion
The main findings of the present study are that FAAH-IR is
associated with prostate cancer disease severity and outcome, that
FAAH-IR and CB1IR give additive prognostic information at
mid-range, but not high CB1IR, and that the correlation of
Table 1. Correlation matrix for FAAH-IR in tumour and non-malignant tissue.
Spearman’s r [no of pairs in correlation] for FAAH-IR in:
Tumour samples (T) Non-malignant tissue samples (N)
parameter epithelial blood vessel basal luminal blood vessel
Epithelial FAAH (T) - 0.37***
[357]
Epithelial FAAH (N):
basal - 0.54***
[307]
0.21***
[299]
luminal - 0.08
NS
[299]
Epithelial CB1IR (T) 0.23***
[370]
0.13*
[344]
Epithelial CB1IR (N) 0.11‘
[293]
0.04
NS
[293]
0.04
NS
[336]
***p,0.001; *p,0.05, ‘not significant (p,0.06),
NSnot significant (p.0.16). CB1IR values are taken from the original data of [14]. The scores for the epithelial FAAH (T),
basal (but not luminal) FAAH (N), blood vessel FAAH (T and N), and epithelial CB1IR (T and N) were not normally distributed (p,0.0001, D’Agostino & Pearson omnibus
normality test).
doi:10.1371/journal.pone.0012275.t001
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PLoS ONE | www.plosone.org 6 August 2010 | Volume 5 | Issue 8 | e12275Figure 2. IL-4 affects FAAH activity in prostate cancer cells. Panel A, IL-4 receptor immunoreactivity in a prostate tumour tissue sample
(Gleason score 8). The line at the bottom left of the picture represents 100 mm. Panels B–D, effect of IL-4 upon the FAAH activity of human PC-3
prostate cancer cells (B); rat R3327 AT-1 prostate cancer cells (C) and mouse P19 teratocarcinoma cells (D). The cell lines were incubated for 24 h with
5 ng/ml of IL-4 and the FAAH activity in cell homogenates was determined using 2 mM[
3H]anandamide as substrate. The enzyme activity in all cases
was totally blocked by the selective FAAH inhibitor URB597. Data are means and s.e.m., n=4–5; *p,0.05, **p,0.01, paired t-test. In Panels (E) and (F)
PC-3 and LNCaP cells were incubated with IL-4 (5 ng/ml) for 24 h. Extraction of RNA, cDNA synthesis and PCR analysis were performed as described in
the ‘Methods’ section. Panel E. Semi-quantitative PCR analysis of FAAH mRNA expression in PC-3 and LNCaP cells. The mRNA expression of FAAH was
normalized against GAPDH. The semi-quantitative PCR analysis was performed using pooled samples (n=6). Panel F. Quantitative real-time PCR
analysis of FAAH mRNA expression, normalized against GAPDH. Quantitative PCR data are visualized as means (n=6) and s.e.m, where the untreated
control group mean is defined as 100%.
doi:10.1371/journal.pone.0012275.g002
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malignant, tissue is consistent with a local dysregulation due to a
component of the tumour microenvironment. These findings raise
four questions:
1. Are the FAAH-IR seen in the tumour tissue consistent
with the literature
To our knowledge, the only study of FAAH in human prostate
cancer tissue samples [12] used a different FAAH antibody and a
commercially available tissue microarray. These authors found a
low incidence of FAAH-IR in normal tissue (1 of 8 cores) whereas
a FAAH expression was seen in 109 of 157 cores for cases of
prostate cancer. In benign prostate hyperplasia the basal cells
expressed FAAH, whereas the luminal cells showed weak FAAH-
IR [12], a finding entirely consistent with our data with the non-
malignant tissue samples. Those authors found that although the
mean FAAH-IR was higher in the tumour samples than in the
normal tissue, there was no obvious relation to the Gleason scores
Table 2. Correlation of tumour FAAH-IR with clinical measures at diagnosis.
Spearman’s r [no of pairs in correlation] for tumour FAAH-IR in:
Parameter: Epithelial cells blood vessels
CB1IR: all ,2 2 2.025–2.25 $2.3 all
Age 20.07
NS
[388]
20.28**
[91]
0.04
NS
[114]
20.15
NS
[83]
20.06
NS
[82]
20.05
NS
[360]
Gleason score 0.21***
[388]
20.12
NS
[91]
0.27**
[114]
0.30**
[83]
0.05
NS
[82]
20.01
NS
[360]
Tumour stage 0.11*
[382]
20.31**
[90]
0.21*
[111]
0.18
NS
[82]
20.004
NS
[81]
0.02
NS
[354]
% of the specimen that contained tumour 0.17**
[388]
20.23*
[91]
0.24*
[114]
0.20‘
[83]
0.06
NS
[82]
0.006
NS
[360]
Incidence of metastases at diagnosis 0.10
NS
[303]
0.14
NS
[74]
0.10
NS
[90]
.004
NS
[58]
0.04
NS
[68]
0.02
NS
[281]
pEGFR 0.18**
[293]
0.06
NS
[73]
0.10
NS
[91]
0.19
NS
[65]
0.16
NS
[49]
0.07
NS
[275]
***p,0.001, **p=0.01, *p,0.05, ‘not significant (p,0.07)
NSnot significant (p.0.08). The CB1IR values are taken from the original data of [14], and intervals chosen
represent the data roughly divided into quartiles. pEGFR-IR values are taken from the original data of [37].
doi:10.1371/journal.pone.0012275.t002
Figure 3. Association of FAAH-IR with prostate cancer outcome. Panel A. Receiver-operated characteristic (ROC) analyses for tumour
epithelial (Epi) and blood vessel (BV) FAAH-IR. A 15 year cut-off was used for the patients who were not treated. For comparative purposes, the ROC
curve for epithelial CB1 receptor IR (Epi CB1IR, from the original data of [14] is shown). The dotted line indicates the result if the parameter under
study has no prognostic value (i.e. area under the ROC curve=0.5). The AUC (95% confidence intervals in brackets) and significance levels were: Epi
FAAH-IR: 0.598 (0.520–0.677), p,0.02); BV FAAH-IR: 0.516 (0.434–0.597), p.0.7; Epi CB1IR (from [14]), 0.665 (0.586–0.744), p,0.0001). The optimal
cutoff (Youden value) for the Epi FAAH-IR (JFAAH) is shown as an open circle on its ROC curve. Panel B, Kaplan-Meier plot for the fraction survival of
patients followed with active expectancy with tumour epithelial FAAH-IR scores of either below or above the JFAAH value (2.354). The number of cases
where death was due to prostate cancer are indicated as {p in the figure. The hatches on the lines show censored data (i.e. cases other than death
due to prostate cancer). The 15-year probabilities of event-free survival for FAAH-IR below and above the JFAAH value were 6764% and 3269%,
respectively.
doi:10.1371/journal.pone.0012275.g003
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larger sample indicates that the medians are similar for the
different Gleason groups, but that there is a significant correlation
between the tumour epithelial FAAH-IR and the Gleason score,
and that there is a higher proportion of cases with a high Gleason
score (8–10) in cores with a high tumour epithelial FAAH-IR than
those with a low FAAH-IR. In prostate cancer, the predominant
epithelial cell type stains for markers of luminal cells [40], and our
finding that the median FAAH-IR in the epithelial tumour cells
was higher than in the luminal cells in the non-malignant cores
would be consistent with the notion of an up-regulation of FAAH
in the tumour tissue.
To our knowledge, the only study investigating FAAH as a
potential prognostic factor for disease outcome is in pancreatic
cancer [41]. These authors found that in a cohort of 29 patients,
cases with a low FAAH-IR showed a poorer prognosis than cases
with a high FAAH-IR. The authors also investigated mRNA using
quantitative PCA in a separate and larger cohort (n=53) and
found that FAAH provided no prognostic information [41]. The
authors pointed out that there were a low number of cancer cells
in the tissue preparations and this, together with the low cohort
sizes, may explain the difference between the mRNA and the IR
data. An additional consideration is the choice of cutoff. In the
present study, the ROC curve for FAAH had an early (but small)
peak, then returned to the line of no diagnostic value before
peaking at the Youden value (shown circled in Fig. 3A. A simple
median split of our data (i.e. essentially as undertaken in [41] as far
as can be ascertained from their Kaplan-Meier curves) would give
cutoffs here of #2 and .2, which is in the region of the ROC
curve where the FAAH-IR lacks prognostic value, and indeed the
Kaplan-Meier plots for these two groups are superimposible, with
15 year disease-specific survival rates of 6266% and 5666% for
the cases with FAAH-IR scores #2 (n=143) and .2 (n=138)
(data not shown). This is in contrast to the situation for the CB1IR,
where the ROC curve is more robust (see Fig. 3A) and the choice
of cutoff is less critical.
2. Is measurement of FAAH in prostate tumour tissue
obtained at diagnosis a potential prognostic marker
The scoring system used in the present study, whereby both
intensity and distribution are measured, is useful for evaluating the
role of FAAH in the pathogenesis of prostate cancer, which was
the aim of the present study, but may be too complex for routine
clinical diagnosis, where a simple intensity score would be
preferable. Even with this caveat, the answer to the question is
‘‘no’’, since a) the area under the ROC curve, albeit significantly
higher than 0.5 (the score for no prognostic value), is modest, and
b) the FAAH-IR does not provide significant additional informa-
tion to that provided by the Gleason scores. A consequence of this
modest ROC value is that the test-retest reliability of the measure
(as assessed by investigating the contribution of the FAAH upon
disease-specific survival of random splits of the data set) is not good
(data not shown). This is in contrast to the situation for CB1IR,
which has a higher area under the ROC curve (0.67), which shows
a robust test-retest reliability, and which provides significant
additional prognostic information to that to that provided by the
Gleason scores [14].
3. How do FAAH and CB1IR contribute to disease severity
and outcome
The data presented here indicate that the degree to which
FAAH is associated with disease severity and outcome are
dependent upon the prevailing CB1IR. Thus, for example, for
the 114 samples with a CB1IR value of 2, there is a clear
correlation of FAAH with the Gleason score, whereas this is not
seen for the samples with a CB1IR$2.3 or for CB1IR,2. In the
Cox proportional-hazards regression analyses, FAAH-IR provided
significant additional information to that provided by CB1IR at
CB1IR cutoffs of $2 and $2.1, but not at $2.5. It is thus worth
considering the role of FAAH at ‘‘mid-range’’ and ‘‘high’’ levels of
CB1 expression.
There are elegant studies for prostate cancer cells showing that
endocannabinoid levels control invasive behaviour in an in vitro
model. Thus, the metabolically stable anandamide analogue
methananadmide and the synthetic cannabinoid WIN55,212-2
reduce the invasivity of androgen-resistant PC-3 and DU-145 (but
not the androgen-sensitive LNCaP) cells, whilst depletion of 2-
arachidonoylglycerol or addition of the CB1 receptor antagonist
rimonabant increases the invasivitiy of the androgen-resistant cells
[8]. PC-3 cells have relatively low levels of FAAH, and transfection
of the cells with FAAH increases both their migration and
invasivity in vitro [12]. Although the step from in vitro models to
man is large, these data do provide a framework for understanding
how a high FAAH-IR, by reducing the local endocanninoid levels,
is associated with disease outcome in cases with a mid-range
expression of CB1IR – in the cases with a low CB1IR, the target
for endocannabinoid action is absent. In this respect, it is worth
pointing out that although 2-AG is usually regarded as a substrate
for monoacylglycerol lipase, FAAH is capable of hydrolysing this
substrate [42], and in some tissues and cells, inhibition of FAAH
results in an increased level of both AEA and 2-AG [43–45].
The relative importance of FAAH and MGL in the metabolism
of 2-AG has been investigated in prostate cancer cells. In intact
PC-3 cells, exogenous 2-AG is hydrolysed by an OTFP
Table 3. Cox proportional-hazards regression analyses for
tumour epithelial FAAH-IR and CB1IR scores.
Variable Categorical value n Exp(B)
1 95% CI p
Univariate analysis
FAAH-IR ,JFAAH=0 228
.JFAAH=1 53 2.151 1.311–3.528 0.005
CB1IR ,2=0 77 3.244 1.609–6.543 ,0.001
$2=1 192
CB1IR ,2.3=0 225 4.402 2.688–7.210 ,0.001
$2.3=1 44
Multivariate analysis
FAAH-IR ,JFAAH=0 217
.JFAAH=1 50 2.189 1.318–3.635 0.002
CB1IR ,2=0 77
$2=1 190 3.354 1.660–6.774 ,0.001
Multivariate analysis
FAAH-IR ,JFAAH=0 217
.JFAAH=1 50 1.690 1.007–2.839 0.047
CB1IR ,2.3=0 223
$2.3=1 44 3.949 2.385–6.540 ,0.001
1For those readers not familiar with the output of a Cox proportional-hazards
regression analysis, exp(B) refers to odds ratio, i.e. the change in odds as a
result of an increase in the ‘‘unit’’ of the predictive variable under study. For
example, FAAH-IR,YFAAH and .YFAAH are given categorical ‘‘units’’ of 0 and 1,
respectively (see [39]). The JFAAH value is 2. 354.
doi:10.1371/journal.pone.0012275.t003
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chidonic acid, which is then metabolised by 12-lipoxygenase to
form 12-hydroxyeicosatetraenoic acid [46]. In our hands, the
hydrolysis of 2-AG by intact PC-3 cells is only marginally inhibited
by the selective FAAH inhibitor URB597, and in the case of
R3327 AT-1 cells, no inhibition is seen [47]. However, trans-
fection of PC-3 cells with FAAH does increase their rate of 2-AG
hydrolysis in addition to the effects on AEA hydrolysis [12].
The above discussion assumes that the CB1 receptors are the
target for the local endocannabinoids, and certainly the in vitro
invasivity data using prostate cancer cell lines would support this
contention [8]. A loss of CB1 receptors would also, according to this
assumption, be deleterious, and this has been reported in colorectal
cancer [48]. The finding that in hepatocellular carcinoma,
individuals with a low expression of CB1 and CB2 receptors have
a poorer prognosis than individuals with a high expression of these
receptors [49] would suggest that a similar mechanism may also be
operative in this cancer form. However, this does not exclude other
potential targets of endocannabinoid, or endocannabinoid metab-
olite, action. TRPV1 receptors are expressed in human prostate
tissue [50,51], so in theory some of the protective properties of AEA
may involve activation of these receptors, given that in other cancer
cell types, AEA can produce apoptosis via such a mechanism [52].
To our knowledge, this possibility has not been investigated in
prostate cancer cells, although the effects of [R]-methanandamide,
the metabolically stable analogue of anandamide, upon the viability
of PC-3 cells are mediated by CB2 rather than TRPV1 receptors
[53]. In addition, it has been proposed that free fatty acids
produced from the corresponding 2-acylglycerols (including 2-
arachidonoylglycerol) by the action of monoacylglycerol lipase may
be involved in the pathogenesis of several tumour types [54], and it
can be argued that FAAH may also play this role in the generation
of free fatty acids from the corresponding N-acylethanolamines
(including anandamide).
At variance with the above discussion is the finding that the
prognostic information supplied by FAAH is lost at a high CB1IR,
and indeed, in both prostate and pancreatic cancers, a high rather
than a low CB1 expression is associated with a poorer outcome
[14,41]. In the pancreatic cancer, this finding was confirmed when
mRNA levels were measured in a separate cohort [41]. However,
a recent article in this Journal has shed light on one possible
mechanism for this variation [55]. These authors constructed
astrocytoma subclones expressing different levels of CB receptors,
and found that the signalling pathways involved upon activation of
the receptors were dependent upon the receptor expression level.
At low levels of receptor expression, the receptors coupled to
Erk1/2 and cannabinoids produced apoptosis. At high levels of
receptor expression, this pathway was still operative, but the
receptors also coupled to Akt, and cannabinoids only produced
apoptosis when this pathway was inhibited [55]. If this is a
generalised phenomenon, then a case can be made that in prostate
cancer, patients with low CB1IR are sensitive to apoptosis
produced by local endocannabinoids (which will be regulated by
FAAH and monoacylglycerol lipase), whilst cases with high CB1IR
will be insensitive to the local endocannabinoid levels. Needless to
say, the step from astrocytoma cells in vitro to prostate cancer is
large, and factors such as changes in receptor reserve (seen in
normal tissues with a high CB1 expression, such as the
hippocampus [56]) may also be of importance. Nonetheless, the
receptor-dependent signalling pathways described in [55] would
explain why the influence of a high FAAH-IR is greater at low
CB1IR than at high CB1IR scores.
A second factor that may be involved in the poor prognosis seen
for patients with a high CB1IR relates to the activation of the
pEGFR pathway. The present study shows that in the tumour
epithelia, FAAH-IR is correlated with the pEGFR-IR, but that
this is secondary to a correlation between CB1IR and pEGFR-IR.
EGFR is an important signalling protein, and aberrant signalling
has been implicated in the pathogenesis of several cancer types,
including prostate cancer (see [37,57]). In human U373-MG
glioblastoma cells, cannabinoids induce a cell proliferation that is
dependent upon the EGFR signalling pathway [58] and in C6 rat
glioma cells, expression of the EGFR ligand amphiregulin is an
important factor controlling their resistance to the apoptosis
produced by cannabinoids [59]. The anti-proliferative effect of
anandamide in prostate cancer cells has also been associated with
a down-regulation of EGFR expression [7].
4. Why is FAAH-IR expression higher in tumour tissue
than in the normal prostate
Our correlation data with FAAH and CB1 provide useful data
in this respect. In theory, there should be no correlation between
two completely independent variables, unless both variables are
both affected in the same manner by a third variable. FAAH and
CB1 receptors are located on different chromosomes [60,61] and
do not appear initially to have co-evolved [62], so there is no
compelling reason why their expression should be correlated in
normal tissue. Indeed, in the non-malignant tissue (which is
admittedly far from normal), there was no correlation at all
between the CB1IR and the FAAH-IR. This is important in itself,
since it would suggest that the two measures are independent, and
that a high CB1IR is not a homeostatic consequence of a low
endocannabinoid signalling secondary to a high FAAH expression.
However, a correlation was seen in the tumour tissue. It is well
known that the tumour microenvironment plays an important role
in the pathogenesis of prostate cancer [63], and it can be
hypothesised that a component of the tumour microenvironment
regulates in the same manner the activity of both CB1 receptors
and FAAH. The observed expression levels will thereby show a
degree of co-variance depending upon the levels of the micro-
environmental regulator, and hence a correlation will be seen.
Although there are a number of potential regulatory sites on the
FAAH promoter [64], few studies have investigated the regulation
of this enzyme in cell systems. To our knowledge the only
molecules known to regulate FAAH activity are the TH1 cytokines
IL-12 and IFNc (which decrease FAAH activity in lymphocytes),
progesterone, leptin, the TH2 cytokines IL-4 and IL-10 (which
increase FAAH activity and FAAH protein content in lympho-
cytes), and follicle stimulating hormone (which increases FAAH
activity in Sertoli cells) [26,65,66]. None of these molecules have
been investigated in prostate cancer cells with respect to FAAH.
IL-4, which is found in the stroma of tumour regions of the
prostate, upregulates anti-apoptotic proteins in prostate cancer
cells [29]. Importantly for the co-variance argument raised above,
IL-4 also increases the expression of CB1 receptors in lymphocytes
[27,28] so we elected to focus on that molecule as a ‘‘test of
concept’’ that a component of the tumour microenvironment can
influence FAAH activity. We could confirm that tumour epithelial
cells express IL-4 receptors, in line with previous studies using both
tumour tissue and cultured cells [29,36], and could demonstrate
that IL-4 increases FAAH activity in a PC-3 and R3327 AT1
prostate cancer cells as well as in P19 teratocarcinoma cells,
indicating it to be a rather general effect of this cytokine. However,
and at variance with the lymphocyte study of [26], we did not
observe any obvious increase in FAAH protein levels following IL-
4 treatment, although as a caveat it should be pointed out that the
Western blot protocol we used was not fully optimised. There were
also no changes in mRNA levels for FAAH in either PC3 or
FAAH in Prostate Cancer
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One possible explanation for these results is that IL-4 treatment
results in a change either in the membrane conformation or in the
cellular disposition of the FAAH in the prostate cancer cells, so
that more is available to the substrate without the need for de novo
synthesis, but such an explanation requires further study.
In conclusion, the present study has demonstrated that tumour
epithelial FAAH-IR is associated with prostate cancer severity and
outcome. A case is made that the FAAH-IR is regulated by the
tumour microenvironment, and a potential candidate molecule,
IL-4, has been investigated in vitro, although contributions by other
components of the tumour environment should certainly be
considered. The present data motivate studies designed to
determine how IL-4 regulates FAAH in prostate cancer cells
compared to lymphocytes, whether stromal IL-4 immunoreactivity
(and/or expression of IL-4 receptors in the tumour epithelia)
correlates with tumour epithelial FAAH-IR in prostate cancer
tissue, and which other components of the tumour microenviron-
ment are potential regulators of the endocannabinoid system.
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